Skip to main content

Advertisement

Table 4 The inter-relationship between clinico-pathological characteristics and blood vessel invasion (BVI FVIII ) in patients with primary operable invasive ductal breast cancer

From: Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer

All patients (n = 360) BVIFVIII-ve BVIFVIII+ ve ( P-value)
n = 301(84%) n = 59(16%)  
Age (≤50/ >50 years) 104/197 21/38 0.848
Size (≤20/ 21-50/ >50 mm) 168/123/10 17/39/3 <0.001
Grade (I / II / III) 45/104/152 3/20/36 0.044
Involved lymph node (-ve/+ve) 185/116 21/38 <0.001
ER status (no/yes) 139/162 32/27 0.258
PR status (no/yes) 158/143 36/23 0.230
HER2 status (no/yes) 250/51 39/20 0.003
Endocrine therapy (no/yes) 226/70 46/11 0.475
Chemotherapy (no/yes) 178/118 31/26 0.419
Tumour recurrence (no/local/distant/both) 243/13/42/3 28/4/25/2 <0.001
Alive/cancer death/non cancer death 179/60/62 10/37/12 <0.001
Cancer specific survival (months)a 181(173–189) 93(73–112) <0.001
Node-negative disease (n = 212) n = 185 (90%) n = 21 (10%)  
Age (≤50/ >50 years) 58/132 10/12 0.157
Size (≤20/ 21-50/ >50 mm) 118/69/3 6/15/1 0.002
Grade (I / II / III) 36/66/88 1/9/12 0.180
ER status (no/yes) 50/66 22/16 0.114
PR status (no/yes) 58/58 23/15 0.261
HER2 status (no/yes) 158/32 16/6 0.228
Endocrine therapy (no/yes) 133/50 16/5 0.732
Chemotherapy (no/yes) 129/54 13/8 0.419
Tumour recurrence (no/local/distant/both) 163/9/15/3 12/0/10/0 <0.001
Alive/cancer death/non cancer death 125/24/41 3/11/8 0.001
Cancer specific survival (months)a 194(186–202) 110(75–146) <0.001
Triple-negative patients (n = 120) n = 104(87%) n = 16(13%)  
Age (≤50/ >50 years) 44/60 6/10 0.718
Size (≤20/ 21-50/ >50 mm) 59/40/5 4/11/1 0.037
Grade (I / II / III) 1/16/87 0/5/11 0.212
Involved lymph node (-ve/+ve) 65/39 5/11 0.019
Endocrine therapy (no/yes) 92/12 15/0 0.167
Chemotherapy (no/yes) 45/59 6/9 0.812
Tumour recurrence (no/local/distant) 81/3/20 7/0/9 0.002
Alive/cancer death/non cancer death 64/24/16 2/13/1 0.014
Cancer specific survival (months)a 172(157–186) 64(37–92) <0.001
  1. a = Mean (95% CI).